🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xi’an
Clinical trial register · China

Clinical Trials in Xi’an, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 44 Guangzhou 29 Shanghai 25 Tianjin 22 Hangzhou 20
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing44 Guangzhou29 Shanghai25 Tianjin22 Hangzhou20
All 57 locations
Target enrolment
to

Trials with a site in Xi’an

7 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
36
Zhengzhou, Nanjing, Xuzhou, Shanghai, Xi’an
2025-12-10
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Not yet open
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
NCT07090954Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1/2
32
Shanghai, Xi'an
2025-08-31
Recruiting
A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
NCT06644118Multiple Myeloma
Zhejiang University
Phase 1
58
Beijing, Xi’an, Hangzhou
2024-10-23
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
Janssen Research & Development, LLC
Phase 4
295
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Nanjing, Shanghai, Xi'an
2022-03-09
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/xi-an

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies with a site in Xi’an that also match the filters currently applied.

How many clinical trials are recruiting in Xi’an?

5 of the 7 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xi’an), 7 studies
PhaseStudiesRecruitingShare
Phase 12228.6%
Phase 1/22128.6%
Phase 31014.3%
Phase 41114.3%
Phase EARLY_PHASE11114.3%

Most active sponsors

Lead sponsors with the most studies (Xi’an)
Lead sponsorStudiesRecruiting
Celgene10
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
Genrix (Shanghai) Biopharmaceutical Co., Ltd.10
Gracell Biotechnologies (Shanghai) Co., Ltd.11
Janssen Research & Development, LLC11
The First Affiliated Hospital with Nanjing Medical University11
Zhejiang University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.